• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Oravig (miconazole)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Oravig (miconazole)

  • Profile

Profile

Contact Information

Contact: Galt Pharmaceuticals
Title: http://www.oravig.com/

Currently Enrolling Trials

    Show More

    General Information

    Oravig contains the active ingredient miconazole, an imidazole antifungal agent. Miconazole works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes.

    Oravig is specifically indicated for the local treatment of oropharyngeal candidiasis in adults.

    Mechanism of Action

    Oravig contains the active ingredient miconazole, an imidazole antifungal agent. Miconazole inhibits the enzyme cytochrome P450 14a-demethylase, which leads to inhibition of ergosterol synthesis, an essential component of the fungal cell membrane. Miconazole also affects the synthesis of triglycerides and fatty acids and inhibits oxidative and peroxidative enzymes, increasing the amount of reactive oxygen species within the cell.

    Side Effects

    Adverse events associated with the use of Oravig may include, but are not limited to, the following:

    • Diarrhea
    • Headache
    • Nausea
    • Dysgeusia
    • Upper abdominal pain
    • Vomiting

    Dosing/Administration

    Oravig is supplied as a 50-mg buccal tablet designed to be dissolved in the gum region. The recommended dose is the application of one 50-mg buccal tablet to the upper gum region once daily for 14 consecutive days.

    Clinical Trial Results

    FDA Approval
    The FDA approval of Oravig was based on the following studies:
     

    HIV-Infected Patients
    This randomized, double-blind, double-dummy, multicenter trial compared Oravig 50 mg once daily for 14 consecutive days (n = 290) with clotrimazole troches 10 mg five times per day for 14 days (n = 287) in HIV-positive patients. Clinical cure was defined as a complete resolution of both signs and symptoms of OPC at the test of cure (TOC) visit (days 17 to 22). The clinical cure was reported by 60.7 percent of subjects in the Oravig arm and 65.2 percent of the Clotrimazole troches arm. Mycological cure was defined as eradication (i.e., no yeast isolates) of Candida species at the TOC visit (days 17 to 22). Mycological cure was reported by 27.2 percent of the Oraig arm and 24 percent of the Clotrimazole troches arm.
     

    Study in Head and Neck Cancer Patients
    This open-label, randomized, multicenter trial compared Oravig 50 mg once daily for 14 days to miconazole oral gel 125 mg four times daily for 14 days in head and neck cancer patients who had received radiation therapy. Success rates of treatment at day 14 (defined as a complete [complete disappearance of candidiasis lesions] or partial response [improvement by at least two points of the score for extent of oral lesion compared with the score at day 1] based on a blind assessment) was reported in 53.4 percent of the Oravig arm and 46.6 percent of the Miconazole oral gel arm. Mycological cure was reported in 44.6 percent of the Oravig arm and 53.4 percent of the Miconazole oral gel arm.

     

     

    Approval Date: 2010-04-01
    Company Name: Strativa Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing